NJ-J.M.-HUBER
The J.M. Huber Corporation announced today that it has signed a definitive agreement to sell the Silica business unit of Huber Engineered Materials (HEM) to Evonik Industries AG—a global specialty chemicals company.
The transaction will include HEM’s Silica facilities in North America, Europe and Asia. Until the transaction closes, Silica continues to operate as part of HEM. For 2016, Huber’s Silica business unit is expected to achieve revenue close to $300 million and an adjusted EBITDA of approximately $60 million.
The sale of Silica will not affect HEM’s other business units, which include Fire Retardant Additives and Ground Calcium Carbonate.
Mike Marberry, President and Chief Executive Officer of Huber, noted, “Silica has been part of Huber since the 1950s and paved the way for the Company’s global expansion in engineered materials. While it is difficult to part with a longstanding business, we expect Evonik to be an excellent fit for our Silica customers and our Silica employees.” The transaction is subject to government approvals and is expected to be completed within the second half of 2017.
Explained Marberry, “Once the deal is closed, Huber expects to redeploy the proceeds from this sale to strategically invest in our core engineered materials businesses to further strengthen our portfolio of specialty products.”
By integrating Huber’s silica operations into its business, Evonik will be able to expand its position primarily in North America and Asia. “Huber Silica will be an outstanding reinforcement for our growth segment Resource Efficiency,” said Klaus Engel, Chairman of the Executive Board of Evonik. “In addition, it will offer the opportunity to strategically develop Evonik’s corporate portfolio.”
Huber’s Silica business is oriented towards the dental care sector. To date, Evonik’s silica business has been focused more strongly on industrial applications, for example in the tire and coatings industry. Bringing together these two entities will create a global integrated silica business that is better positioned to serve customers around the world.
Representing J.M. Huber in the transaction were BofA Merrill Lynch, Moelis & Company LLC, and Jones Day.
About J.M. Huber Corporation (www.huber.com )
J.M. Huber Corporation, headquartered in Edison, New Jersey (U.S.), operates a portfolio of companies with a focus on its core engineered materials businesses. Founded in 1883, today Huber is one of the largest family-owned companies in the U.S. The diversified, multinational company creates products that are used in a broad range of consumer and industrial applications, including fire retardant additives and smoke suppressants, personal care, food, beverage, pharmaceuticals and building materials.
About Huber Engineered Materials (www.hubermaterials.com )
Huber Engineered Materials, headquartered in Atlanta, Georgia (U.S.), is a global business focused on engineered specialty ingredients that enhance the performance, appeal and processing of a broad range of products used in industrial and consumer-based applications. With an expertise in inorganic materials, it has a portfolio of high value products: specialty silicas and silicates, alumina trihydrate, magnesium hydroxide, molybdate compounds and industrial, food and USP grade calcium carbonate.
About Evonik Industries AG (www.evonik.com )
Evonik is a global leader in specialty chemicals, active in more than 100 countries world-wide. In its fiscal year 2015, more than 33.500 employees generated sales of about Euro 13.5 billion and an operative, adjusted EBITDA of about Euro 2.47 billion.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161209005413/en/
Contact:
J.M. Huber Corporation
Robert Currie, 732-603-5746
r.currie@Huber.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom